LEXICON PHARMACEUTICALS, INC.LXRX
LEXICON PHARMACEUTICALS, INC. Segments Disclosure
Segment Information
Lexicon operates as a single reportable segment, primarily focusing on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company’s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales, as well as from commercial sales of its approved drug product.
The chief operating decision maker (“CODM”) is the Company’s chief executive officer (“CEO”). The CEO manages and allocates resources on a total company basis by assessing the overall level of resources available and how to best deploy these resources across research and development projects in line with the Company’s long-term company-wide strategic goals.
The CEO evaluates single-segment consolidated financial information against budget for purposes of making operating decisions, planning and forecasting for future periods, and deciding the level of investment in the Company’s various operating activities and other capital allocation activities. The CODM assesses financial performance based on consolidated net income (loss) (as reported on the consolidated statement of comprehensive loss). The CEO also uses consolidated cash and cash equivalents and short-term investments (which can be found on our Consolidated Balance Sheets) as a measure of segment assets for allocating resources.
Summary of segment net loss, including segment expenses were as follows:
| Years Ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| (in thousands) | ||||||||||||||||||||
| Revenues: | ||||||||||||||||||||
| Net product revenue | $ | 4,647 | $ | 6,001 | $ | 1,110 | ||||||||||||||
| Licensing revenue | 45,000 | 25,000 | — | |||||||||||||||||
| Royalties and other revenue | 156 | 80 | 94 | |||||||||||||||||
| Total revenues | 49,803 | 31,081 | 1,204 | |||||||||||||||||
| Operating expenses: | ||||||||||||||||||||
| Cost of sales | 274 | 616 | 85 | |||||||||||||||||
| Research and development | 54,586 | 77,549 | 53,748 | |||||||||||||||||
| Sales and marketing | 6,143 | 97,265 | 77,561 | |||||||||||||||||
| General and administrative | 25,232 | 26,991 | 25,786 | |||||||||||||||||
Other segment expense (1) (2) | 12,479 | 25,777 | 15,774 | |||||||||||||||||
| Total operating expenses | 98,714 | 228,198 | 172,954 | |||||||||||||||||
| Loss from operations | (48,911) | (197,117) | (171,750) | |||||||||||||||||
| Interest and other expense | (8,339) | (15,579) | (13,101) | |||||||||||||||||
| Interest income and other, net | 6,909 | 12,293 | 7,732 | |||||||||||||||||
| Net loss | $ | (50,341) | $ | (200,403) | $ | (177,119) | ||||||||||||||
(1) For the years ended December 31, 2025, 2024 and 2023, other segment expense includes stock compensation of $6.3 million, $5.8 million and $5.1 million related to research and development personnel, respectively; $0.04 million, $2.0 million and $2.3 million related to sales and marketing personnel, respectively; and $6.2 million, $5.7 million and $6.9 million related to general and administrative personnel.
(2) For the year ended December 31, 2024, other segment expenses include severance costs of 1.1 million related to research and development personnel, $9.3 million related to sales and marketing personnel and $1.9 million related to general and administrative personnel. Total severance costs included in other segment expenses for the year ended December 31, 2023 was $1.4 million, which related to sales and marketing personnel.
Significant Customers. In support of the commercial launch of INPEFA in 2023, the Company entered into distribution agreements with wholesalers and limited retail pharmacies. The Company’s net product sales are generated from sales to these customers. In 2025, 2024 and 2023, twelve United States-based customers accounted for all of the Company’s net product revenue. Three large wholesalers accounted for greater than 10% of total net product revenues and in the aggregate accounted for greater than 80% of total revenues for each year. Net product revenue for each of the three wholesalers were $1.7 million, $1.1 million and $0.9 million in 2025, $2.3 million, $1.4 million and $1.4 million in 2024 and $0.4 million, $0.3 million and $0.3 million in 2023. In 2025, royalties and other revenues derived from two customers and in 2024 and 2023, one customer accounted for royalties and other revenues. For further information regarding the Company’s licensing revenue agreement, see Note 7.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Mar 7, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.